Identification of patients with triple antiphospholipid antibody positivity is platform and method independent

Polskie Archiwum Medycyny Wewnetrznej

Volumn 126, Issue 1-2, 2016, Pages 19-24

  Iwaniec, Teresa ^a   Kaczor, Marcin P ^a   Celinska Löwenhoff, Magdalena ^a   Polanski, Stanislaw ^a   Musial, Jacek ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Chemiluminescent immunoassay; Enzyme linked immunosorbent assay; Triple positivity

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; CHEMOLUMINESCENCE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; COMPARATIVE STUDY; FEMALE; MEASUREMENT ACCURACY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CROSS-SECTIONAL STUDIES; DATA ACCURACY; FEMALE; HUMANS; IMMUNOASSAY; LUPUS ERYTHEMATOSUS, SYSTEMIC; RETROSPECTIVE STUDIES;

EID: 84958259506     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.3259     Document Type: Article

References (24)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4: 295-306.
2. Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: A cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol. 2002; 118: 548-557.
3. Wong R, Favaloro E, Pollock W, et al. A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays. Pathology. 2004; 36: 182-192.
4. Reber G, Tincani A, Sanmarco M, et al. Variability of anti-beta2 glycoprotein I antibodies measurement by commercial assays. Thromb Haemost. 2005; 94: 665-672.
5. Swadzba J, Iwaniec T, Szczeklik A, Musial J. Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases. J Thromb Haemost. 2007; 5: 1883-1889.
6. Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005; 93: 1147-1152.
7. Mustonen P, Lehtonen KV, Javela K, Puurunen M. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: A nationwide prospective study. Lupus. 2014; 23: 1468-1476.
8. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: A multicenter prospective study. Blood. 2011; 118: 4714-4718.
9. Pengo V, Denas G, Padayattil S, et al. Diagnosis and therapy of antiphospholipid syndrome. Pol Arch Med Wewn. 2015; 125: 672-677.
10. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010; 8: 237-242.
11. Ruffatti A, Calligaro A, Del RT, et al. Risk-based secondary prevention of obstetric antiphospholipid syndrome. Lupus. 2012; 21: 741-743.
12. Pengo V, Ruffatti A, Del RT, et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost. 2013; 11: 1527-1531.
13. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25: 1271-1277.
14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1725.
15. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009; 7: 1737-1740.
16. Bertolaccini ML, Amengual O, Andreoli L, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014; 13: 917-930.
17. De Moerloose P, Reber G, Musial J, Arnout J. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J Thromb Haemost. 2010; 8: 1540-1546.
18. Andreoli L, Tincani A. Beyond the "syndrome": Antiphospholipid antibodies as risk factors. Arthritis Rheum. 2012; 64: 342-345.
19. Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012; 64: 504-512.
20. Sciascia S, Bertolaccini ML. Thrombotic risk assessment in APS: The Global APS Score (GAPSS). Lupus. 2014; 23: 1286-1287.
21. Chung Y, Kim JE, Lim HS, Kim HK. Clinical performance of anticardiolipin and antiβ2 glycoprotein I antibodies using a new automated chemiluminescent assay: Superior thrombotic prediction of combined results measured by two different methods. Blood Coagul Fibrinolysis. 2014; 25: 10-15.
22. Meneghel L, Ruffatti A, Gavasso S, et al. The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-beta2 glycoprotein I antibodies. A comparison with a homemade ELISA method. Clin Chem Lab Med. 2015; 53: 1083-1089.
23. Forastiero R. Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation. Lupus. 2014; 23: 1252-1254.
24. Lim W. Thrombotic risk in the antiphospholipid syndrome. Semin Thromb Hemost. 2014; 40: 741-746.